» Articles » PMID: 14586680

Catch-up Growth with Normal Parathyroid Hormone Levels in Chronic Renal Failure

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2003 Oct 31
PMID 14586680
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The optimum range for parathyroid hormone (PTH) levels in children with chronic renal failure (CRF) remains undefined. We aimed to determine growth velocity in children with CRF managed with normal PTH levels. We performed a retrospective case note review of 99 children (77 boys), with a glomerular filtration rate (GFR) <41 ml/min per 1.73 m(2), who had at least 2 years of 3-monthly follow-up. The age range at entry was 0.5-6.0 years; data collection was continued until 10 years of age or the commencement of growth hormone or renal replacement therapy. The median GFR was 22 ml/min per 1.73 m(2); over the study period mean serum calcium and phosphate levels were approximately equal to the mid-point of the respective normal ranges. Median PTH levels were equal to the upper limit of the normal range. Height standard deviation score (Ht SDS) at entry was -1.73. During the study period the overall mean change in Ht SDS was +0.3, significantly greater than the no change expected of a normal population ( P=0.004). The median dose of calcium carbonate was 150 mg/kg per day and 1-alpha calcidol 0.015 microg/kg per day. The growth rate was independent of all parameters, including age, PTH levels, the use of enteral feeds, and 1-alpha calcidol prescription. Our results indicate that catch-up growth can occur in infants and children with CRF when medical therapy is aimed at normalizing PTH levels.

Citing Articles

Chronic kidney disease: mineral and bone disorder in children.

Wesseling-Perry K, Salusky I Semin Nephrol. 2013; 33(2):169-79.

PMID: 23465503 PMC: 4209124. DOI: 10.1016/j.semnephrol.2012.12.017.


Growth hormone in chronic renal disease.

Gupta V, Lee M Indian J Endocrinol Metab. 2012; 16(2):195-203.

PMID: 22470855 PMC: 3313736. DOI: 10.4103/2230-8210.93736.


Early skeletal and biochemical alterations in pediatric chronic kidney disease.

Wesseling-Perry K, Pereira R, Tseng C, Elashoff R, Zaritsky J, Yadin O Clin J Am Soc Nephrol. 2011; 7(1):146-52.

PMID: 22052943 PMC: 3265337. DOI: 10.2215/CJN.05940611.


Parathyroid hormone and growth in chronic kidney disease.

Waller S Pediatr Nephrol. 2010; 26(2):195-204.

PMID: 20694820 DOI: 10.1007/s00467-010-1614-y.


Middle-term use of Cinacalcet in paediatric dialysis patients.

Platt C, Inward C, McGraw M, Dudley J, Tizard J, Burren C Pediatr Nephrol. 2009; 25(1):143-8.

PMID: 19838738 DOI: 10.1007/s00467-009-1294-7.


References
1.
Hutchison A, Whitehouse R, Boulton H, Adams J, Mawer E, Freemont T . Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993; 44(5):1071-7. DOI: 10.1038/ki.1993.350. View

2.
Salusky I, Goodman W . The management of renal osteodystrophy. Pediatr Nephrol. 1996; 10(5):651-3. DOI: 10.1007/s004670050183. View

3.
Sanchez C, Kuizon B, Abdella P, Juppner H, Salusky I, Goodman W . Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. Endocrinology. 2000; 141(4):1536-44. DOI: 10.1210/endo.141.4.7436. View

4.
Norman L, Coleman J, MacDonald I, Tomsett A, Watson A . Nutrition and growth in relation to severity of renal disease in children. Pediatr Nephrol. 2001; 15(3-4):259-65. DOI: 10.1007/s004670000465. View

5.
Block G, Port F . Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000; 35(6):1226-37. DOI: 10.1016/s0272-6386(00)70064-3. View